Collins Helen Louise
SEC CIK 1701247 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | Chief MEDICAL Off | 30.0K | — | $5.91M | 25 | 2024-04-11 | 2026-09-17 |
Most active insiders at ELVN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 10% | — | $51.68M |
| 2 | Derynck Mika K | Dir | — | $9.56M |
| 3 | Collins Helen Louise | Chief MEDICAL Off | — | $5.39M |
| 4 | Lyssikatos Joseph P | CSO | — | $4.88M |
| 5 | Patel Anish | COO | — | $1.74M |
| 6 | Hohl Benjamin | CFO | — | $1.60M |
| 7 | Kunkel Lori Anne | Dir | — | $850.3K |
| 8 | Kintz Samuel | Pres AND CEO, Dir | — | $613.6K |
| 9 | Heyman Richard A. | Dir | — | $413.4K |
Transactions 25
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-21 17:22 | 2026-09-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +5,000 | 30.0K | +20% | +$12.4K |
| DMT | 2026-09-21 17:22 | 2026-09-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $50.35 | -5,000 | 25.0K | -17% | -$251.8K |
| DT | 2026-08-19 16:16 | 2026-08-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +5,000 | 30.0K | +20% | +$12.4K |
| DMT | 2026-08-19 16:16 | 2026-08-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $58.59 | -5,000 | 25.0K | -17% | -$292.9K |
| DT | 2026-07-21 17:23 | 2026-07-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +5,000 | 30.0K | +20% | +$12.4K |
| DMT | 2026-07-21 17:23 | 2026-07-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $52.67 | -5,000 | 25.0K | -17% | -$263.4K |
| DT | 2026-06-22 17:11 | 2026-06-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +5,000 | 30.0K | +20% | +$12.4K |
| DMT | 2026-06-22 17:11 | 2026-06-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $43.80 | -5,000 | 25.0K | -17% | -$219.0K |
| DT | 2026-05-20 16:18 | 2026-05-18 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +5,000 | 30.0K | +20% | +$12.4K |
| DMT | 2026-05-20 16:18 | 2026-05-18 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $39.79 | -5,000 | 25.0K | -17% | -$199.0K |
| DT | 2026-04-21 20:40 | 2026-04-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +5,000 | 30.0K | +20% | +$12.4K |
| DMT | 2026-04-21 20:40 | 2026-04-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $47.67 | -5,000 | 25.0K | -17% | -$238.4K |
| D | 2026-03-27 | 2026-03-25 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +40.0K | 65.0K | +160% | +$99.2K |
| D | 2026-03-27 | 2026-03-25 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $35.10 | -40.0K | 25.0K | -62% | -$1.40M |
| D | 2026-03-19 | 2026-03-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $27.76 | -5,000 | 25.0K | -17% | -$138.8K |
| D | 2026-03-19 | 2026-03-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +5,000 | 30.0K | +20% | +$12.4K |
| DM | 2026-03-11 | 2026-03-09+ | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $30.06 | -40.0K | 25.0K | -62% | -$1.20M |
| DM | 2026-03-11 | 2026-03-09+ | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +40.0K | 54.9K | +269% | +$99.2K |
| D | 2026-02-19 | 2026-02-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $26.17 | -45.0K | 25.0K | -64% | -$1.18M |
| D | 2026-02-19 | 2026-02-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +45.0K | 70.0K | +180% | +$111.6K |
| D | 2026-02-17 | 2026-02-12 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | A - Grant | $0.00 | +25.0K | 25.0K | New | $0 |
| D | 2024-10-22 | 2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $30.00 | -816 | 0 | -100% | -$24.5K |
| D | 2024-10-22 | 2024-10-18 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +816 | 816 | New | +$2,024 |
| D | 2024-04-15 | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | M - OptEx | $2.48 | +20.0K | 20.0K | New | +$49.6K |
| D | 2024-04-15 | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief MEDICAL Off | S - Sale+OE | $25.07 | -20.0K | 0 | -100% | -$501.4K |
Purchase Sale Sale after option exercise All abbreviations